Alzecure Pharma Q1’21: Our Comment

Research Note

2021-05-05

14:10

Redeye gives its first impression on Alzecure’s Q1’21 report. Overall, the burn-rate was very much as expected

AH

Anders Hedlund

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.